Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376734 · ClinicalTrials.gov registry record · Phase 2
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
A Phase 2 study of Schizophrenia and Major Depressive Disorder, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 2
- Study locations
NCT06376734 is a Phase 2 study of Schizophrenia and Major Depressive Disorder that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 180 participants, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (17% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06376734, a Phase 2 study of Schizophrenia and Major Depressive Disorder, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 2
- Study locations
Study Summary
Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.
Conditions Studied
Interventions
- DEVICE Transcranial magnetic stimulation
Study Locations (2)
California
- Acacia Clinics - Sunnyvale
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2030-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06376734
The ClinicalTrials.gov registry entry for NCT06376734 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (17% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Transcranial magnetic stimulation is the first listed.
NCT06376734 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06376734 about?
NCT06376734 is a clinical study titled "Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness". Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.
What is the current status of trial NCT06376734?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-01-30. Estimated completion is 2030-06-01.
What conditions does trial NCT06376734 study?
This clinical trial studies the following conditions: Schizophrenia, Major Depressive Disorder, Obsessive - Compulsive Disorder, Generalized Anxiety Disorder, Mood Disorders.
What interventions are being tested in trial NCT06376734?
The interventions under investigation include: Transcranial magnetic stimulation (DEVICE).
Who is sponsoring clinical trial NCT06376734?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376734 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
-
A Study of ANAVEX3-71 in Adults With Schizophrenia
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.